BioCentury | Jan 13, 2021
Product Development

Why Verve chose base editing over standard CRISPR for its lead CV candidate

Verve’s non-human primate data makes the case that base editing can produce durable and efficient changes in protein production by the liver, with a clear route to protection from heart attack. Six-month data shared by...
BioCentury | Nov 19, 2020
Emerging Company Profile

Umoja launches with $53M round to test cell therapy cocktails that expand CAR T cells within patients

Umoja’s assembly of a three-step platform could allow the newly launched start-up to create off-the-shelf cell therapy cocktails that expand CAR T cells within patients to treat solid tumors or hematologic malignancies. Named for a...
BioCentury | Mar 27, 2020
Emerging Company Profile

Redpin debuts chemogenetic platform for neurology, raises $15.5M

Redpin emerged from stealth Wednesday with a $15.5 million series A round and a chemogenetics platform designed to treat neurological disorders by controlling neuron excitability. 4Bio Capital and Arkin Bio Ventures led the tranched round....
BioCentury | Feb 8, 2020
Tools & Techniques

Beyond PROTACs and the proteasome: broadening the TAC toolbox

The idea of sending disease-driving proteins to the cell’s garbage can is only the first act in a field that now centers around targeted degradation. In the sequel, researchers are extending the principle to other...
BioCentury | Jan 18, 2020
Product Development

Charting a course to intercepting Type I diabetes

Arguably, the most important innovations on the horizon for Type I diabetes would replace the insulin-producing cells patients have lost or prevent at-risk individuals from losing the cells in the first place. With Provention planning...
BioCentury | Nov 21, 2019
Emerging Company Profile

ShapeTx: Shaping up RNA editing

With its RNAfix platform, Shape is developing therapeutics that are designed to edit RNA in vivo by hijacking an enzyme in the target cell that naturally converts one RNA base to another. The company raised...
BioCentury | Oct 7, 2019
Emerging Company Profile

Gene editing vets launch Korro to convert RNA bases

A trio of gene editing industry veterans have teamed up to launch Korro Bio as their second company developing antisense-based therapies in less than a year. Korro is creating a new CRISPR-independent version of RNA...
BioCentury | Jun 27, 2019
Product Development

Gene therapy’s next frontier lies beyond rare, monogenic diseases

As in vivo gene therapies continue notching approvals for rare monogenic diseases, the next frontier for the modality will be in treating complex indications without obvious genetic drivers. At least seven companies have clinical or...
BioCentury | May 16, 2019
Emerging Company Profile

SNIPR: Turning CRISPR into a microbiome suicide

SNIPR is using CRISPR to target specific bacteria to fight infection or modulate the immune system. Growing interest in CRISPR for mammalian cells and microbiome-focused therapeutics led the company's co-founders, Christian Grøndahl, Morten Sommer and...
BioCentury | Apr 12, 2019
Product Development

Changing models and minds to improve access to addiction treatment

A lack of acknowledgment by key stakeholders in the healthcare system that medications can treat opioid abuse, along with a fragmented reimbursement system, means that effective treatments aren’t getting to the majority of patients who...
Items per page:
1 - 10 of 197
BioCentury | Jan 13, 2021
Product Development

Why Verve chose base editing over standard CRISPR for its lead CV candidate

Verve’s non-human primate data makes the case that base editing can produce durable and efficient changes in protein production by the liver, with a clear route to protection from heart attack. Six-month data shared by...
BioCentury | Nov 19, 2020
Emerging Company Profile

Umoja launches with $53M round to test cell therapy cocktails that expand CAR T cells within patients

Umoja’s assembly of a three-step platform could allow the newly launched start-up to create off-the-shelf cell therapy cocktails that expand CAR T cells within patients to treat solid tumors or hematologic malignancies. Named for a...
BioCentury | Mar 27, 2020
Emerging Company Profile

Redpin debuts chemogenetic platform for neurology, raises $15.5M

Redpin emerged from stealth Wednesday with a $15.5 million series A round and a chemogenetics platform designed to treat neurological disorders by controlling neuron excitability. 4Bio Capital and Arkin Bio Ventures led the tranched round....
BioCentury | Feb 8, 2020
Tools & Techniques

Beyond PROTACs and the proteasome: broadening the TAC toolbox

The idea of sending disease-driving proteins to the cell’s garbage can is only the first act in a field that now centers around targeted degradation. In the sequel, researchers are extending the principle to other...
BioCentury | Jan 18, 2020
Product Development

Charting a course to intercepting Type I diabetes

Arguably, the most important innovations on the horizon for Type I diabetes would replace the insulin-producing cells patients have lost or prevent at-risk individuals from losing the cells in the first place. With Provention planning...
BioCentury | Nov 21, 2019
Emerging Company Profile

ShapeTx: Shaping up RNA editing

With its RNAfix platform, Shape is developing therapeutics that are designed to edit RNA in vivo by hijacking an enzyme in the target cell that naturally converts one RNA base to another. The company raised...
BioCentury | Oct 7, 2019
Emerging Company Profile

Gene editing vets launch Korro to convert RNA bases

A trio of gene editing industry veterans have teamed up to launch Korro Bio as their second company developing antisense-based therapies in less than a year. Korro is creating a new CRISPR-independent version of RNA...
BioCentury | Jun 27, 2019
Product Development

Gene therapy’s next frontier lies beyond rare, monogenic diseases

As in vivo gene therapies continue notching approvals for rare monogenic diseases, the next frontier for the modality will be in treating complex indications without obvious genetic drivers. At least seven companies have clinical or...
BioCentury | May 16, 2019
Emerging Company Profile

SNIPR: Turning CRISPR into a microbiome suicide

SNIPR is using CRISPR to target specific bacteria to fight infection or modulate the immune system. Growing interest in CRISPR for mammalian cells and microbiome-focused therapeutics led the company's co-founders, Christian Grøndahl, Morten Sommer and...
BioCentury | Apr 12, 2019
Product Development

Changing models and minds to improve access to addiction treatment

A lack of acknowledgment by key stakeholders in the healthcare system that medications can treat opioid abuse, along with a fragmented reimbursement system, means that effective treatments aren’t getting to the majority of patients who...
Items per page:
1 - 10 of 197